TRUE Private Wealth Advisors Buys 497 Shares of Eli Lilly and Company $LLY

TRUE Private Wealth Advisors lifted its position in Eli Lilly and Company (NYSE:LLY) by 7.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,366 shares of the company’s stock after purchasing an additional 497 shares during the quarter. Eli Lilly and Company comprises about 0.6% of TRUE Private Wealth Advisors’ investment portfolio, making the stock its 28th biggest position. TRUE Private Wealth Advisors’ holdings in Eli Lilly and Company were worth $5,742,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $27,000. Financial Gravity Companies Inc. bought a new stake in Eli Lilly and Company in the second quarter worth $31,000. Blume Capital Management Inc. increased its position in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the second quarter valued at $35,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on LLY shares. Scotiabank began coverage on shares of Eli Lilly and Company in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price on the stock. CICC Research lifted their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and increased their price target for the company from $886.00 to $1,104.00 in a report on Monday, November 10th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,020.37.

Eli Lilly and Company Stock Up 0.9%

Shares of NYSE:LLY opened at $1,030.49 on Wednesday. The firm has a market capitalization of $974.21 billion, a PE ratio of 67.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The business has a 50 day simple moving average of $838.20 and a two-hundred day simple moving average of $782.36. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,040.72. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the business posted $1.18 earnings per share. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.